Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.71 |
| ▸ | AURKA | O14965 | 1/20 | 0.71 |
| ▸ | INSR | P06213 | 1/20 | 0.71 |
| ▸ | IGF1R | P08069 | 1/20 | 0.71 |
| ▸ | CDK4 | P11802 | 1/20 | 0.71 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | AHR | P35869 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | SRC | P12931 | 1/20 | 0.66 |
| ▸ | KDR | P35968 | 7/20 | 0.65 |
| ▸ | LCK | P06239 | 5/20 | 0.65 |
| ▸ | RET | P07949 | 2/20 | 0.63 |
| ▸ | FLT1 | P17948 | 1/20 | 0.63 |
| ▸ | GAK | O14976 | 1/20 | 0.63 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.63 |
| ▸ | STK10 | O94804 | 1/20 | 0.63 |
| ▸ | FLT3 | P36888 | 1/20 | 0.63 |
| ▸ | JAK3 | P52333 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6180313 | 0.99 | EGFR (0.70) | EGFRAURKAINSRIGF1RCDK4 | |
| SCHEMBL4931410 | 0.87 | MAPT (0.66) | EGFRAURKAINSRIGF1RCDK4 | |
| SCHEMBL5652185 | 0.84 | KDR (0.80) | KDR | |
| SCHEMBL4758836 | 0.83 | MAPT (0.60) | EGFRAURKAINSRIGF1RCDK4 | |
| SCHEMBL4935871 | 0.83 | RAF1 (0.64) | EGFRAURKAINSRIGF1RCDK4 | |
| SCHEMBL14026144 | 0.81 | MAPT (0.77) | EGFRMAPTMAPK1AHRHTT | |
| SCHEMBL4890611 | 0.81 | EGFR (0.67) | EGFRAURKAINSRIGF1RCDK4 | |
| SCHEMBL4938676 | 0.81 | MAPT (0.60) | EGFRAURKAINSRIGF1RCDK4 | |
| SCHEMBL4008515 | 0.81 | MAPT (0.80) | EGFRMAPTMAPK1AHRHTT | |
| SCHEMBL4937051 | 0.81 | KDR (0.62) | EGFRAURKAAURKBMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0871448-B1 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | AVENTIS PHARMA INC (US) | 2005-03-02 | — | — | EP | claimed |
| US-20080311076-A1 | Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents | ARROW THERAPEUTICS LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| EP-1748991-A1 | MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | Arrow Therapeutics Limited (GB) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005105761-A1 | MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311076-A1 | Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents | EIF2AK2, MAVS, IRF3 | EGFR 3952/4885AURKA 2081/4885INSR 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.